Press coverage about Repligen Corporation (NASDAQ:RGEN) has been trending somewhat positive on Friday, Accern Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Repligen Corporation earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.1276739011992 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Repligen Corporation (RGEN) Cut to Hold at Zacks Investment Research (americanbankingnews.com)
- Repligen Corp Shares Up 29.4% Since SmarTrend’s Buy Recommendation (RGEN) (mysmartrend.com)
- Repligen Corporation (RGEN) Raised to B- at TheStreet (americanbankingnews.com)
- Brokerages Anticipate Repligen Corporation (RGEN) Will Announce Quarterly Sales of $34.66 Million (americanbankingnews.com)
- See what the IHS Markit Score report has to say about Repligen Corp. (finance.yahoo.com)
A number of brokerages have issued reports on RGEN. BidaskClub raised shares of Repligen Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research raised shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Saturday, August 12th. TheStreet raised shares of Repligen Corporation from a “c+” rating to a “b-” rating in a research report on Friday, August 11th. Finally, First Analysis reaffirmed an “equal weight” rating and issued a $40.00 price objective on shares of Repligen Corporation in a research report on Friday, April 21st. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $42.00.
Repligen Corporation (NASDAQ:RGEN) traded up 1.26% on Friday, hitting $40.21. 265,261 shares of the stock were exchanged. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of 78.69 and a beta of 1.30. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81. The company has a 50-day moving average of $41.60 and a 200-day moving average of $36.97.
Repligen Corporation (NASDAQ:RGEN) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.05. The business had revenue of $32.40 million during the quarter, compared to analysts’ expectations of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The business’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.16 earnings per share. On average, equities analysts predict that Repligen Corporation will post $0.59 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/18/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-repligen-corporation-rgen-share-price.html.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
